Elucid
Utilizes AI driven CT angiography analysis to quantify arterial plaque and patient risk.
What they do
Provides non invasive imaging software that uses AI to analyze CT angiography scans, performing virtual histology to quantify plaque composition and assess stability. Cardiologists use the tool to predict ischemic events and customize patient treatment plans.
The record
- Vertical
- Cardiovascular
- Sub-segment
- Cardiovascular imaging AI
- Product type
- Software as a medical device
- Stage
- Series C+
- Headquarters
- Boston, United States
- Region
- North America
- Founded
- 2013
- Total funding
- $121M raised
Notable investors: Elevage Medical Technologies, Industry Ventures, Bold Brain Ventures, Medtech Convergence Fund.